High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients

Pathogens

Ines Ait Belkacem¹  Martina Giudice²  Antonella Minutolo²  Vita Petrone²  Sandro Grelli²  Emanuela Balestrieri²  Claudia Matteucci²  Paola Sinibaldi-Vallebona²  Marialaura Fanelli²  Guido Rasi²  Fabrice Malergue³  Marta Zordan⁴  Loredana Sarmati⁴  Marco Iannetta⁴  Massimo Andreoni⁴  Pietro Vitale⁵ 

[1] CNRS, INSERM, CIML, Centre d’Immunologie de Marseille-Luminy, Aix Marseille Université, 13009 Marseille, France;Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy;Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, 13009 Marseille, France;Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy;Infectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, Italy;

关键词: cytokine storm;    COVID-19;    CD169;    inflammation;    respiratory outcome;    T-cell exhaustion;   

DOI  :  10.3390/pathogens10121639

来源: DOAJ

【 摘 要 】

Background: Sialoadhesin (CD169) has been found to be overexpressed in the blood of COVID-19 patients and identified as a biomarker in early disease. We analyzed CD169 in the blood cells of COVID-19 patients to assess its role as a predictive marker of disease progression and clinical outcomes. Methods: The ratio of the median fluorescence intensity of CD169 between monocytes and lymphocytes (CD169 RMFI) was analyzed by flow cytometry in blood samples of COVID-19 patients (COV) and healthy donors (HDs) and correlated with immunophenotyping, inflammatory markers, cytokine mRNA expression, pulmonary involvement, and disease progression. Results: CD169 RMFI was high in COV but not in HDs, and it correlated with CD8 T-cell senescence and exhaustion markers, as well as with B-cell maturation and differentiation in COV. CD169 RMFI correlated with blood cytokine mRNA levels, inflammatory markers, and pneumonia severity in patients who were untreated at sampling, and was associated with the respiratory outcome throughout hospitalization. Finally, we also report the first evidence of the specific ability of the spike protein of SARS-CoV-2 to trigger CD169 RMFI in a dose-dependent manner in parallel with IL-6 and IL-10 gene transcription in HD PBMCs stimulated in vitro. Conclusion: CD169 is induced by the spike protein and should be considered as an early biomarker for evaluating immune dysfunction and respiratory outcomes in COVID-19 patients.

【 授权许可】

Unknown